Coherus Will Launch US Lucentis Biosimilar By 2021
Deal With Bioeq Pulls Forward Ranibizumab Launch By Two Years
Executive Summary
Buoyed by the success of its Udenyca pegfilgrastim biosimilar, Coherus has struck a deal with Bioeq to acquire commercialization rights to its biosimilar version of Lucentis (ranibizumab) in the US, eyeing a launch date of 2021.
You may also be interested in...
Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.
Formycon Delay Pushes Back Coherus’ Ranibizumab
Formycon and Bioeq’s US filing for a biosimilar ranibizumab rival to Lucentis has been delayed after the FDA requested further data following a manufacturing change. Rights to the biosimilar have been licensed exclusively to Coherus in the US.
Coherus Acquires Bevacizumab Rights From Innovent
Coherus BioSciences has struck a deal with China’s Innovent Biologics that gives it US and Canadian rights to a bevacizumab biosimilar version of Avastin as well as an option to market Innovent’s rituximab rival to Rituxan in the US and Canada.